Literature DB >> 18540894

Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors.

J Blatny, S Kohlerova, O Zapletal, V Fiamoli, M Penka, O Smith.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18540894     DOI: 10.1111/j.1365-2516.2008.01767.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  6 in total

1.  Increased Accumulation and Retention of rhFVIIa (eptacog beta) in Knee Joints of Hemophilia A Mice Compared to Wild-Type Mice.

Authors:  Jhansi Magisetty; Usha R Pendurthi; SubbaRao V Madhunapantula; Jerry Grandoni; L Vijaya Mohan Rao
Journal:  Thromb Haemost       Date:  2019-05-26       Impact factor: 5.249

2.  Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy.

Authors:  D M Cohn; M Goddijn; S Middeldorp; J C Korevaar; F Dawood; R G Farquharson
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

3.  rFVIIa transported from the blood stream into tissues is functionally active.

Authors:  R Gopalakrishnan; U Hedner; C Clark; U R Pendurthi; L V M Rao
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

4.  Animal models of FVIIa gene expression: their role in the future development of haemophilia treatment.

Authors:  A Obergfell; T Nichols; M Ezban
Journal:  Haemophilia       Date:  2010-03       Impact factor: 4.287

5.  Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa).

Authors:  R Gopalakrishnan; U Hedner; S Ghosh; R C Nayak; T C Allen; U R Pendurthi; L V M Rao
Journal:  J Thromb Haemost       Date:  2009-11-23       Impact factor: 5.824

6.  Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa.

Authors:  C A Clark; R Vatsyayan; U Hedner; C T Esmon; U R Pendurthi; L V M Rao
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.